Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD6-H82E2 | Human | Biotinylated Human B7-2 / CD86 Protein, Avitag™,His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-H82F5 | Human | Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD6-M52H0 | Mouse | Mouse B7-2 / CD86 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-M5251 | Mouse | Mouse B7-2 / CD86 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-C5254 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-C52H5 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (HPLC-verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
CD6-H5223 | Human | Human B7-2 / CD86 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD6-H5257 | Human | Human B7-2 / CD86 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).
FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).
Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Abatacept | BMS-188667SC; ONO-4164; BMS-188667; ONO-4164SC | Approved | Bristol-Myers Squibb Company | Orencia | Mainland China | Arthritis, Rheumatoid | s:28:"Bristol-Myers Squibb Company"; | 2005-12-23 | Nephrosis, Lipoid; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Arthritis, Psoriatic; Colitis, Ulcerative; Glomerulosclerosis, Focal Segmental; Psoriasis; Lupus Erythematosus, Systemic; Polymyositis; Lupus Nephritis; Multiple Sclerosis; Arthritis, Juvenile; Coronavirus Disease 2019 (COVID-19); Sjogren's Syndrome; Arthritis, Rheumatoid; Dermatomyositis; Giant Cell Arteritis | Details |
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | EU | Rejection of renal transplantation | s:32:"Bristol-Myers Squibb Pharma Eeig"; | 2011-06-15 | Rejection of renal transplantation; Rejection of organ transplantation | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech | Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.